title: Cognitive screening in patients with intracranial tumors: validation of the BCSE.
abstract: This study presents the first validation of the Brief Cognitive Status Exam (BCSE) against two other screening tools for cognitive impairment in patients with intracranial tumors. 58 patients and 22 matched healthy controls completed the BCSE, the Mini Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA). Patients were additionally tested with a comprehensive neuropsychological battery. Based on this assessment, they were classified as cognitively impaired or unimpaired on five cognitive domains. Analyses revealed a comparable feasibility of the BCSE relative to the MoCA and the MMSE, but a smaller range of assessed functions (e.g., no correlation with the domain visual-spatial functions). The ability to separate patients and healthy controls was extremely poor for BCSE and MMSE (sensitivity of 38.6 % and less), but moderate for MoCA (sensitivity 68.97 %). Detection of cognitive impairment in patients was worst with BCSE (sensitivity 37 %; MoCA 92.9 %, MMSE 44.4 %) as compared to neuropsychological testing. Moreover, prediction of cognitive outcome was also worst for the BCSE (AUC = .713, NPV = 50 %). An optimal cut-off of 50.5 increased the results slightly. In summary, the BCSE showed good feasibility but no sufficient results in separating healthy individuals from patients or detecting cognitive impairment in patients. Consequently, as a screening measure, we would recommend the MoCA instead of the BCSE. However, since even the MoCA failed to detect cognitive impairment, our study supports the view that reliable results could only be obtained with a comprehensive neuropsychological battery.
authors.affiliation: Department of Neurosurgery, University Hospital Schleswig-Holstein, Arnold-Heller-Straße 3, 24105, Kiel, Germany. juliane.becker@uksh.de.
authors.forename: Juliane
authors.initials: J
authors.lastname: Becker
authors.affiliation: Department of Neurosurgery, University Hospital Schleswig-Holstein, Arnold-Heller-Straße 3, 24105, Kiel, Germany.
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Steinmann
authors.affiliation: Department of Neurosurgery, University Hospital Schleswig-Holstein, Arnold-Heller-Straße 3, 24105, Kiel, Germany.
authors.forename: Maria
authors.initials: M
authors.lastname: Könemann
authors.affiliation: Department of Neurosurgery, University Hospital Schleswig-Holstein, Arnold-Heller-Straße 3, 24105, Kiel, Germany.
authors.forename: Sonja
authors.initials: S
authors.lastname: Gabske
authors.affiliation: Department of Neurosurgery, University Hospital Schleswig-Holstein, Arnold-Heller-Straße 3, 24105, Kiel, Germany.
authors.forename: Hubertus Maximilian
authors.initials: HM
authors.lastname: Mehdorn
authors.affiliation: Department of Neurosurgery, University Hospital Schleswig-Holstein, Arnold-Heller-Straße 3, 24105, Kiel, Germany.
authors.forename: Michael
authors.initials: M
authors.lastname: Synowitz
authors.affiliation: Department of Psychology, University of Kiel, Kiel, Germany.|Department of Neuropsychology, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany.
authors.forename: Gesa
authors.initials: G
authors.lastname: Hartwigsen
authors.affiliation: Department of Neurosurgery, University Hospital Schleswig-Holstein, Arnold-Heller-Straße 3, 24105, Kiel, Germany.
authors.forename: Simone
authors.initials: S
authors.lastname: Goebel
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001932:Brain Neoplasms / Q000150:complications* / Q000523:psychology; D016022:Case-Control Studies; D003072:Cognition Disorders / Q000175:diagnosis* / Q000209:etiology / Q000523:psychology; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000379:methods*; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D009483:Neuropsychological Tests; D011379:Prognosis; D011446:Prospective Studies
keywords: Intracranial tumor; Neuropsychological diagnostic; Screening instrument
references.citation: Lancet. 2002 Nov 2;360(9343):1361-8
references.pmid: 12423981
references.citation: J Neurol Neurosurg Psychiatry. 2012 Nov;83(11):1112-7
references.pmid: 22851612
references.citation: J Int Neuropsychol Soc. 2006 Nov;12(6):896-900
references.pmid: 17064451
references.citation: Clin Cancer Res. 2007 Mar 15;13(6):1675-83
references.pmid: 17363520
references.citation: Lancet. 2006 Apr 15;367(9518):1262-70
references.pmid: 16631882
references.citation: Support Care Cancer. 2011 Nov;19(11):1849-55
references.pmid: 20957394
references.citation: J Neurooncol. 2012 Jun;108(2):319-26
references.pmid: 22350433
references.citation: J Neurooncol. 2012 Jun;108(2):227-30
references.pmid: 22451194
references.citation: J Natl Compr Canc Netw. 2003 Jul;1(3):344-74
references.pmid: 19761069
references.citation: J Clin Oncol. 2003 Oct 1;21(19):3557-8
references.pmid: 12913103
references.citation: Arch Clin Neuropsychol. 2004 Mar;19(2):203-14
references.pmid: 15010086
references.citation: Int Psychogeriatr. 2014 Jul 31;:1-9
references.pmid: 25079232
references.citation: Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1168-73
references.pmid: 18495375
references.citation: Ann Neurol. 2000 Apr;47(4):470-6
references.pmid: 10762158
references.citation: Neurochirurgie. 2009 Jun;55(3):303-8
references.pmid: 18822437
references.citation: Support Care Cancer. 2006 Nov;14(11):1111-8
references.pmid: 16538498
references.citation: J Neurooncol. 2012 Jun;108(2):269-75
references.pmid: 22362371
references.citation: J Neurooncol. 2008 Feb;86(3):321-7
references.pmid: 17926007
references.citation: Cancer. 1950 Jan;3(1):32-5
references.pmid: 15405679
references.citation: J Am Geriatr Soc. 2005 Apr;53(4):695-9
references.pmid: 15817019
references.citation: J Neurosurg. 2012 Nov;117(5):831-8
references.pmid: 22937930
references.citation: Clin Neuropsychol. 2009 May;23(4):675-90
references.pmid: 18923969
references.citation: J Psychiatr Res. 1975 Nov;12(3):189-98
references.pmid: 1202204
references.citation: Lancet Neurol. 2004 Mar;3(3):159-68
references.pmid: 14980531
references.citation: J Neurol Sci. 2014 Aug 15;343 (1-2):176-9
references.pmid: 24880539
references.citation: Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):59-64
references.pmid: 10924972
references.citation: Biometrics. 1988 Sep;44(3):837-45
references.pmid: 3203132
references.citation: Crit Rev Oncol Hematol. 2007 Sep;63(3):183-202
references.pmid: 17678745
references.citation: J Clin Oncol. 2006 Mar 10;24(8):1305-9
references.pmid: 16525186
references.citation: Can J Psychiatry. 2007 May;52(5):329-32
references.pmid: 17542384
references.citation: J Clin Oncol. 2000 Feb;18(3):646-50
references.pmid: 10653880
references.citation: J Clin Oncol. 2003 Jul 1;21(13):2519-24
references.pmid: 12829670
references.citation: J Neuropsychiatry Clin Neurosci. 1997 Spring;9(2):189-97
references.pmid: 9144098
references.citation: J Neurooncol. 2011 Jul;103(3):541-9
references.pmid: 20878206
references.citation: J Neurooncol. 2013 May;112(3):455-60
references.pmid: 23417320
references.citation: Support Care Cancer. 2008 Nov;16(11):1273-8
references.pmid: 18335256
references.citation: Acta Neurochir (Wien). 2014 Feb;156(2):367-74
references.pmid: 24254135
references.citation: J Neurooncol. 2011 Nov;105(2):337-44
references.pmid: 21520004